Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo.

Biochimica et biophysica acta - 1 May 2010

Zurawska Anna, Urbanski Jakub, Matuliene Jurgita, Baraniak Janina, Klejman Marcin P, Filipek Slawomir, Matulis Daumantas, Bieganowski Pawel

Abstract excerpt

Hsp90 inhibitors are currently tested in clinical trials as anticancer agents. We investigated whether inhibitor resistance may arise as a result of a point mutation in Hsp90. We used yeast cells that expressed human Hsp90beta to select inhibitor-resistant mutants from the randomly mutagenized library. Single amino acid substitution, I123T, in a selected mutant was sufficient to confer inhibitor resistance....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to Chaperonins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Immunoprecipitation

Share to In Vitro Techniques

Share to Lactams, Macrocyclic

Share to Molecular Chaperones

Share to Two-Hybrid System Techniques

Source

Identifiers

PMID: 20226818
DOI: 10.1016/j.bbamcr.2010.03.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo.PMID 20226818Read ↗

A yeast-based assay reveals a functional defect of the Q488H polymorphism in human Hsp90alpha.Semantic proximity Read ↗

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.Semantic proximity Read ↗

Systematic Mutant Analyses Elucidate General and Client-Specific Aspects of Hsp90 Function.Semantic proximity Read ↗

Single nucleotide polymorphism that accompanies a missense mutation (Gln488His) impedes the dimerization of Hsp90.Semantic proximity Read ↗

Management of Hsp90-Dependent Protein Folding by Small Molecule Targeting the Aha1 Co-ChaperoneSemantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Middle domain of human Hsp90 isoforms differentially binds Aha1 in human cells and alters Hsp90 activity in yeast.Semantic proximity Read ↗

Hsp90: A Global Regulator of the Genotype-to-Phenotype Map in Cancers.Semantic proximity Read ↗

Dominant negative mutations in yeast Hsp90 indicate triage decision mechanism targeting client proteins for degradation.Semantic proximity Read ↗

Cancer-Related Somatic Mutations in Transmembrane Helices Alter Adenosine A1 Receptor Pharmacology.Semantic proximity Read ↗

The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.